In addition, NXP800 reduced both basal, and HSP90 inhibitor-induced, HSP72 protein expression levels, in contrast to its inactive chemical control CCT365248, confirming its important effect in blocking HSF1-activated HSP expression in prostate cancer cells (Supplementary Fig. S4D). The gene discussed is HSF1; the disease is prostate carcinoma.